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Summary 
 
 
Lipid nanoparticles (LN) made of synthetic lipids Compritol® 888 ATO and 
Precirol® ATO 5 were developed, presenting an average size of 110.4 ± 2.1 nm 
and 103.1 ± 2.9 nm, for Compritol® and Precirol®, respectively, and 
encapsulation efficiency above 85 % for both type of lipids. These LN decrease 
the hemolytic toxicity of the drug by 90 %. Pharmacokinetic and biodistribution 
profiles of the drug were studied after intravenous and oral administration of 
edelfosine-containing LN, providing an increase in relative oral bioavailability of 
1500 % after a single oral administration of drug-loaded LN, maintaining 
edelfosine plasma levels over 7 days in contrast to a single oral administration 
of edelfosine solution, which presents a relative oral bioavailability of 10 %. 
Moreover, edelfosine-loaded LN showed a high accumulation of the drug in 
lymph nodes and resulted in slower tumor growth than the free drug in a murine 
lymphoma xenograft model, as well as potent extranodal dissemination 
inhibition.  
 
 
Key Words: edelfosine, lipid nanoparticles, bioavailability, pharmacokinetics, 
biodistribution, lymphoma 
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1. Introduction 
 
 
Edelfosine is considered the prototype of a promising class of antitumor 
agents, collectively known as alkyl-lysophospholipid analogues or antitumor 
ether lipids. These agents present the singular characteristic of not targeting the 
DNA, but affecting the cell membrane and the apoptotic machinery of the 
cancer cell [1]. Recent in vitro studies have shown that edelfosine is 
preferentially uptaken by tumoral cells, sparing normal cells [2].  
However, edelfosine presents some drawbacks when administered 
intravenously, as dose-dependent hemolysis that hampers its administration at 
certain doses [3]; and gastrointestinal irritation when administered orally [4, 5]. 
In addition, edelfosine presents bioavailability values below 10 % after a single 
oral administration of 30 mg/kg; however, this bioavailability increased to 64 % 
after multiple oral administration of the same dose after six days [2].  
Owing to the drawbacks of this molecule, there has been an attempt to 
design new drug delivery systems that can modify the absorption rate, 
selectively transport the drug to the target, modifying the drug distribution profile 
and extending the drug release time in order to improve drug bioavailability, and 
decrease its toxicity. Among the different lipid-made colloidal carriers, 
edelfosine was incorporated into liposomes [6] and lipid nanoparticles (LN) 
made of biocompatible lipids [7]. The liposomal formulation was able to prevent 
the hemolytic toxicity of the drug, but the main inconvenience found was its 
rapid clearance from plasma. Edelfosine-loaded liposomes showed both in vivo 
and in vitro activity against methylnitrosourea-induced tumors, and it was 
approximately 4 - 8 times less acutely toxic than free edelfosine. Edelfosine-
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loaded LN developed by our group were considered another alternative to 
deliver the drug to the organism [7]. These carriers are colloidal transporters 
composed of a biocompatible and biodegradable lipid matrix. They combine 
advantages of liposomes, polymeric nanoparticles and emulsions, while 
diminishing possible drawbacks associated with them [8]. Lipids employed to 
form these lipid cores are biodegradable raw materials that are biocompatible: 
triglycerides (i.e. tristearin), partial glycerides (i.e. Compritol® 888 ATO and 
Precirol® ATO 5), fatty acids (i.e. stearic acid), steroids (i.e. cholesterol) or 
waxes (i.e. cetyl palmitate) [9]. The formulation methods are also diverse [9, 
10]. However, most techniques employ organic solvents, which may imply 
regulatory and toxicity issues. Moreover, an improvement of LN over the 
liposomes is their physical and chemical long-term stability up to 12 - 24 months 
[11]. The freeze-drying process of LN has been shown to increase their 
physicochemical stability over long periods of time [12]. Besides, LN have 
attracted rising interest for their ability to overcome certain biological barriers, 
resulting in increased therapeutic efficacy of the encapsulated drug and 
increase in tumor accumulation [13].  
Mantle cell lymphoma (MCL) is a B-cell malignancy that comprises about 7 
% of all non-Hodgkin’s lymphomas (NHLs), which is characterized clinically by 
extranodal disease in older male patients who present at an advanced stage 
[14]. Even though most patients initially gain a benefit from systemic treatments, 
the responses obtained are generally of limited duration. As a result, patients 
generally relapse with less responsive disease, showing a consistently bad 
outcome with a median overall survival from diagnosis of 43 months [15, 16]. 
Several approaches using more severe combination chemotherapy, namely 
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stem cell transplantation, have shown higher response rates and more lasting 
remission in selected patients, but the greater part of MCL patients are not 
candidates for such dose-intensive regimens [17, 18]. MCL has recently 
become an area of intense clinical research, and it appears that median overall 
survival may be improving, but MCL is still considered incurable with current 
treatments [19]. Although several cytotoxic combinations including cisplatin, 
gemcitabine, carmustine and other alkylating drugs have been employed, their 
inherent toxicity is considered the main drawback at the time of election [20].  
In a previous study, we determined that edelfosine displays a biexponential 
pharmacokinetic behavior in mice, presenting no significant differences 
regardless of the mouse strain employed [2]. The tissue distribution of 
edelfosine in mice shows that the drug is widely scattered across different 
organs, although it is preferentially internalized by the tumor both in vitro and in 
vivo. The present work tries to point out how the biodistribution and 
pharmacokinetic profile of edelfosine is altered compared to that of the free 
drug, when it is encapsulated in LN. The efficacy of the chemotherapeutic 
potential of edelfosine loaded LN via the oral route in experimental murine 
lymphoma xenograft model was also evaluated. 
 
2. Materials and Methods 
2.1. Chemicals 
Edelfosine was from APOINTECH (Salamanca, Spain). Compritol® 888 
ATO and Precirol® ATO 5 were a gift from Gattefossé (Lyon, France). Tween® 
80 was obtained from Roig Farma (Barcelona, Spain). Platelet Activating Factor 
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(PAF) and PBS (10 mM phosphate, 0.9 % NaCl) were obtained from Sigma-
Aldrich (Madrid, Spain). Chloroform was purchased from Panreac (Madrid, 
Spain) and methanol was obtained from Merck (Barcelona, Spain). All other 
solvents were of analytical grade. 
 
2.2. Preparation of LN incorporating edelfosine 
LN were prepared by the hot homogenization method followed by high shear 
homogenization and ultrasonication. The lipid phase consisted of either 
Compritol® 888 ATO or Precirol® ATO 5 along with edelfosine, while the 
aqueous phase consisted of a 2 % (w/v) Tween® 80 aqueous solution. The 
aqueous phase was heated at about 5 ºC above the melting point of the lipid 
and added to the melted lipid phase at the same temperature. The mixture was 
dispersed with the help of a MicrosonTM ultrasonic cell disruptor (NY, USA) for 1 
minute. The preformed emulsion was then homogenised in an Ultraturrax® (IKA-
Werke, Germany) for 1 minute and sonicated again with the MicrosonTM 
ultrasonic cell disruptor (NY, USA) for 1 minute. The nanoparticle suspension 
was cooled in an ice bath and washed twice with filtered water by diafiltration 
with Amicon Ultra-15 filters of 10,000 dalton molecular weight cut-off membrane 
(Millipore®, Cork, Ireland) to remove the excess of surfactant. Nanoparticles 
were then resuspended in PBS for animal administration or in 10 % trehalose 
solution for freeze-drying. 
 
2.3. Characterization of edelfosine loaded LN 
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2.3.1. Particle size and zeta potential 
The average particle size and polydispersity index of edelfosine loaded LN 
were determined by photon correlation spectroscopy (PCS) using a Zetasizer 
Nano (Malvern Instruments, UK). Each sample was diluted 30 fold in distilled 
water until the appropriate concentration of particles was achieved to avoid 
multiscattering events. The obtained monodisperse suspension was examined 
to determine the volume, mean diameter, size distribution and polydispersity 
and repeated three times for each sample. Similarly, the zeta potential was 
measured using the same equipment with a combination of Laser Doppler (LD) 
electrophoresis [21, 22]. Samples were diluted with distilled water (pH 5.5) and 
each experiment was performed in triplicate. All data are expressed as a mean 
value ± standard deviation. 
 
2.3.2 Loading capacity 
Edelfosine was quantified by an ultra high-performance liquid 
chromatography tandem mass spectrometry (UHPLC-MS/MS) method that had 
been previously validated [23]. The drug was extracted from a sample of 10 mg 
of lyophilized nanoparticles, to which 1 ml of chloroform was added in order to 
dissolve them. 10 µL of the internal standard PAF (0.2 mg/mL) were then 
spiked to the samples. 3 mL of methanol were added to the mixture, and after 
vortex mixing for 1 min at room temperature and centrifuging at 20,000 × g for 
10 min, 2 µL aliquots of the supernatant were injected into the chromatographic 
system. 
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2.4. Hemolysis experiments 
Erythrocytes from fresh human blood were separated from plasma by 
centrifugation (4,000 x g, 7 min) and washed three times with PBS. 4 mL of the 
washed erythrocyte suspension were diluted to 100 mL with PBS. 1.5 mL of this 
suspension were treated with 0.5 mL of tested samples: free edelfosine (10 
µg/mL), edelfosine loaded Compritol® and Precirol® nanoparticles (10 µg/mL) 
and drug free Compritol® and Precirol® nanoparticles. Absorbance was 
measured in an Agilent 8453 UV-visible spectrophotometer (Agilent, Palo Alto, 
CA, USA) at 540 nm 1 h after the treatment. 
 
2.5. Animal experiments  
Animal handling was conducted in compliance with the regulations of the 
Ethical Committee of the University of Navarra as well as with the European 
Community Council Directive Ref. 86/609/EEC. For pharmacokinetic studies, 
BALB/c mice (20 g) were obtained from Harlan Interfauna Ibérica S.L. 
(Barcelona, Spain). For efficacy studies, SCID mice (Janvier, Genest St Isle, 
France) were employed. Animals received a standard diet and water ad libitum, 
except for the animals that received the oral doses, which were fasted for 24 
hours prior to administration. 
 
2.5.1. Pharmacokinetic and biodistribution studies after intravenous 
administration  
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An i.v. single dose of edelfosine-loaded LN (50 mg/kg) was administered to 
BALB/c (n=8 per group) mice via the tail vein. Group 1 received Compritol® 888 
ATO LN and group 2, Precirol® ATO 5 LN. At various time points after 
administration (0, 1, 2, 5, 8, 24 and 31 h for Compritol® group and 0, 1, 2, 5, 8, 
24, 48, 72, 96, 120, 144 and 168 h for Precirol® group), blood was collected in 
EDTA surface-coated tubes and then centrifuged at 2,000 × g for 10 min (4 ºC) 
to separate the plasma (100 µL). Then, animals were sacrificed and spleen, 
liver, lungs, kidneys, heart, stomach and intestine were collected and weighed. 
Tissues were homogenised in 1 mL of PBS pH=7.4 using a Mini-bead Beater 
(BioSpect Products, Inc., Bartelsville, Oklahoma, USA) and centrifuged at 
10,000 × g for 10 min. Both plasma and tissue supernatants were collected and 
stored at -80 ºC until UHPLC-MS/MS analysis was performed. 
 
2.5.2. Pharmacokinetic and biodistribution studies after oral 
administration 
Three BALB/c mice groups (n=8 per group) were treated with a single oral 
administration of free edelfosine (50 mg/kg) and edelfosine-loaded LN 
(edelfosine concentration of 50 mg/kg). Group 1 was treated with an oral 
administration of free edelfosine; group 2 received Compritol® 888 ATO LN and 
group 3, Precirol® ATO 5 LN. At various time points after the administration (0, 
1, 2, 5, 8, 24, 48, 72, 96, 120, 144 and 168 h for free drug and Compritol® 
groups and 0, 1, 2, 5, 8, 24, 48, 72, 96, 120, 144, 168, 192 and 216 h for 
Precirol® group), blood was collected in EDTA surface-coated tubes and then 
centrifuged at 2,000 × g for 10 min (4 ºC) to collect plasma (100 µL). After 
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sacrifice by cervical dislocation, tissues were collected, weighed and processed 
as explained above.  
 
2.5.3. Lymphatic absorption studies 
BALB/c mice (n=8 per group) received oral doses of free edelfosine (group 1), 
Compritol LN (group 2) and Precirol LN (group 3) (edelfosine concentration of 
50 mg/kg). 24 hours later, an oily emulsion (milk) was orally administered 1 hour 
prior to sacrifice, in order to make the lymph ducts and nodes more visible, 
animals were sacrificed and mesenteric lymph nodes were spotted close to the 
ascending colon, extracted with the aid of dissection forceps. Then, they were 
processed like the rest of the organs and analyzed by UHPLC-MS/MS. 
 
2.5.4. Efficacy studies  
Cell culture studies 
The human mantle-cell lymphoma cell line JVM-2 (DSMZ, Germany) was 
grown in RPMI-1640 containing 10 % heat-inactivated fetal calf serum 
(GIBCO/BRL, Carlsbad, CA, USA), 2 mM of L-glutamine, 100 µg/ml 
streptomycin sulphate (Sigma) and 100 U/ml penicillin (Sigma), at 37 ºC in a 
humidified atmosphere of air containing 5 % CO2. 
Animal studies 
Eight-week SCID mice were subcutaneously inoculated into the lower 
dorsum with 1 x 107 JVM-2 cells in 100 µL of PBS and 100 µL of Matrigel 
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basement membrane matrix (Becton Dickinson, San Jose, CA). Animals 
received a standard diet and water ad libitum. When tumors were palpable, 
mice were randomly assigned to the treatment groups. Six groups of mice (n=8 
per group) were treated orally: group 1: PBS; group 2: edelfosine solution (30 
mg/kg dissolved in PBS); group 3: edelfosine-loaded Compritol® 888 ATO 
nanoparticles (edelfosine concentration of 30 mg/kg); group 4: edelfosine-
loaded Precirol® ATO 5 nanoparticles (edelfosine concentration of 30 mg/kg); 
group 5: blank Compritol® 888 ATO nanoparticles (10 mg/mL lipid 
concentration); and group 6: blank Precirol® ATO 5 nanoparticles (10 mg/mL 
lipid concentration, equivalent to a 30 mg/kg edelfosine dose). The treatments 
were administered by oral gavage every four days. The experiment ended when 
control group tumors reached a volume of 5.0±0.5 cm3. At this point, animals 
were sacrificed and tumors were collected for the determination of their volume 
and weight. Axilary, inguinal and mesenteric lymph nodes were also extracted 
from MCL-bearing mice treated with either free or vectorized edelfosine and 
macroscopically analyzed. 
 
2.6. Data analysis  
Pharmacokinetic analysis was performed with plasma samples obtained 
from experiments with all mice. All these plasma concentration data were 
analyzed by non-compartmental and compartmental analysis using WinNonlin 
Professional Edition Version 2.1 (Pharsight, Mountain View, CA, USA). The 
area under the plasma concentration vs. time curve (AUC) was determined 
using the log-linear trapezoidal rule with extrapolation to infinitum and 
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normalized against the dose. The CL value is the volume of plasma completely 
cleared of a specific compound per unit time by the organism; it was calculated 
by dividing the dose by AUC. The maximum plasma concentration (Cmax) was 
calculated from the plasma concentration-time curve and normalized against 
the dose. Oral bioavailability (F) was determined by ratio of the dose-normalized 
AUC following oral and i.v. administration. Vss is the volume of fluid that would 
be required to contain the amount of drug in the body if it were uniformly 
distributed at a concentration equal to that in the plasma. The t1/2 value refers to 
the time taken for plasma concentration to fall by 50 %, and it was determined 
using the following formula: t1/2=ln (2)·Vss/CL. 
 
2.7. Statistical analysis  
The presence of differences in tissue/plasma ratios and pharmacokinetic 
parameters was measured by the Mann Whitney test for double comparisons 
using Social Package of Statistical Sciences (SPSS). Student’s t test was used 
for measuring differences in efficacy and tumor dissemination inhibition studies. 
A value of p < 0.05 was considered to be statistically significant for all statistical 
tests. 
 
3. Results and discussion 
3.1. Particle size, size distribution and zeta potential 
The peroral route is the most preferred route of administration, but this path 
is limited for many substances as they present poor oral bioavailability due to 
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biopharmaceutical (low solubility, low permeability, and/or instability in 
gastrointestinal environment) and pharmacokinetic (extensive first pass 
metabolism and/or rapid clearance) drawbacks in their delivery approach. 
Therefore, the development of delivery systems that would be able to overcome 
these drawbacks is essential to ensure the effectiveness of such molecules. 
Edelfosine-loaded LN were produced by a solvent-free hot homogenization 
method followed by high shear homogenization and ultrasonication, and freeze-
dried. The physical-chemical characteristics of the developed nanoparticles are 
compiled in Table I.  
 
Table I. Average size, PDI, zeta potential, encapsulation efficiency (EE) and drug 
loading of edelfosine-loaded LN (n=20) prepared by the warm microemulsion formation 
followed by high shear homogenization and ultrasonication method. 
	  
	  
 
LN Size (nm) PDI ζ Potential (mV) %EE 
Drug loading (µg 
edelfosine/mg form.) 
Drug-free 
Compritol® LN 130.6 ± 3.1 0.275 ± 0.021 -28.6 ± 2.1 --- --- 
Drug-loaded 
Compritol® LN 
110.4 ± 2.1 0.261 ± 0.050 -21.2 ± 1.5 84.68 ± 7.18 17.57 ± 1.97 
Drug-free 
Precirol® LN 
117.7 ± 2.4 0.243 ± 0.026 -29.1 ± 1.7 --- --- 
Drug-loaded 
Precirol® LN 103.1 ± 2.9 0.231 ± 0.012 -22.4 ± 2.0 82.62 ± 5.73 13.95 ± 0.79 
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All data are expressed as mean value ± standard deviation. Drug-free LN 
presented diameters of 130.6 ± 3.1 and 117.7 ± 2.4 for Compritol® and Precirol® 
LN, respectively. The average diameter of edelfosine-loaded Compritol® LN was 
110.4 ± 2.1 nm, while drug-loaded Precirol® LN presented a mean diameter of 
103.1 ± 2.9 nm, suggesting that edelfosine might be responsible for the 
reduction in size of LN, as it is a surfactant structured molecule. These particles 
present a smaller size than those prepared by the emulsion formation and 
solvent evaporation method previously developed [7]. This method therefore 
provides smaller particles, which are organic solvent-free, in a shorter 
formulation time. PDI was below 0.3 in all cases indicating that the LN were 
monodisperse. These particles present an appropriate size for their oral 
administration, since it has been widely demonstrated that sizes below 300 nm 
are suitable for intestinal transport to the thoracic duct [24-27].  
Zeta (ζ) potential can make a prediction about the stability of colloid 
dispersions. A high ζ potential (>|30| mV) can provide an electric repulsion to 
avoid the aggregation of particles, as they are considered strongly ionic [21, 
28]. In our case, the ζ-potential values measured in double-distilled water were 
negative. The mean ζ potentials of edelfosine-loaded and drug-free Compritol® 
LN were -21.2 ± 1.5 mV and -28.6 ± 2.1 mV, respectively. Precirol® LN showed 
similar values of -22.4 ± 2.0 mV and -29.1 ± 1.7 mV for edelfosine-loaded and 
drug-free Precirol® LN, respectively. The incorporation of edelfosine slightly 
modified the zeta potential of the LN, supporting the idea of existence of drug in 
the surface of the LN along with the Tween® 80. This negative surface charge 
could be due to the presence of oleic acid traces in Tween® 80 on the particle 
surface, forming a denser surfactant film, and thus eliciting increased 
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electrophoretic mobility. Besides, the steric impediment of Tween® 80 might be 
another effect which would increase the stability of colloidal dispersions [29]. 
 
3.2. Loading capacity 
It is well known that the crystalline state in the LN structure leads to faster 
drug expulsion. However, lattice defects of the lipid structure offer space to 
accommodate the drugs [30]. As a result, the structure of less ordered 
arrangement in the nanoparticles should be beneficial to the drug loading 
capacity, as in the case of the particles developed in this work.  
The entrapment efficiency of edelfosine in the LN prepared by the warm 
microemulsion followed by high shear homogenization and ultrasonication was 
similar for nanoparticles prepared with both types of lipids (Table I). 
Nanoparticles formulated using Compritol® encapsulated 84.68 ± 7.18 % of 
edelfosine (equivalent to 17.57 ± 1.97 µg edelfosine/mg formulation), while 
Precirol® LN encapsulated 82.62 ± 5.73 % of the drug (13.95 ± 0.79 µg 
edelfosine/mg formulation). This high encapsulation efficiency is likely to be due 
to the partially amorphous state of the lipids in the formulation, which allows 
more edelfosine to be incorporated among lipid chains [7]. 
 
3.3. Hemolytic experiments  
Edelfosine presents hemolytic toxicity due to its amphipathic structure 
[31]. Therefore, a hemolytic assay was performed to assess whether LN 
reduced the hemolytic effect of edelfosine. Results clearly showed that LN 
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protected red blood cells from hemolysis caused by edelfosine, because while 
the free drug was 100 % hemolytic at 10 µg/mL, both drug-loaded and unloaded 
LN only presented 9.88 and 12.02 % of hemolysis at the same drug 
concentration, for Compritol® and Precirol® respectively. This means that the 
low hemolysis produced was due to the LN composition itself, more concretely 
to the Tween® 80 present on the surface of the LN, rather than to the effect of 
the drug. In previous studies, Kötting et al. determined that in an in vitro study a 
50% of spontaneous hemolysis was caused by a concentration of 2 µmol/L of 
edelfosine within 2 minutes [31]. In an in vivo study Ahmad et al. revealed that 
approximately 5% of circulating red blood cells hemolysed in 30 minutes after a 
single i.v. dose of 50 mg/kg [3]. As a result, LN showed a significant decrease in 
hemolytic toxicity of edelfosine.  
 
3.4. Pharmacokinetic characterization and biodistribution after intravenous 
administration  
Figures 1A and 1B show the concentration of edelfosine in mouse plasma 
plotted against time after a single i.v. administration of edelfosine-loaded LN 
(concentration ranging 30 - 60 mg/kg) to BALB/c mice. Dose-normalized 
pharmacokinetic analysis of edelfosine in blood plasma showed a Cmax of 
approximately 0.3 µg/mL for both types of LN, showing no statistical differences 
between them. All obtained pharmacokinetic parameters were dose-normalized 
and are listed in Table II.  
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Figure 1. Time-concentration curve data of edelfosine after a single intravenous 
administration of edelfosine loaded (A) Compritol® and (B) Precirol® LN to BALB/c mice 
(n=8, mean ± S.D.) 
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Table II. Comparison of pharmacokinetic parameters of edelfosine after intravenous 
administration of edelfosine loaded LN (50 mg/kg bw, n=8 per group, mean ± SD). No 
statistical differences were found among parameters p>0.05. 
Parameters 
Compritol® 888 ATO LN 
i.v. administration 
Precirol® ATO 5 LN 
i.v. administration 
t½α (h) 0.395 ± 0.124 0.505 ± 0.151 
t½β (h) 16.970 ± 5.775 23.718 ± 17.743 
Cmax / D (µg/mL/µg) 0.290 ± 0.087 0.341 ± 0.044 
CL (L/h/kg) 0.105 ± 0.021 0.065 ± 0.023 
Vss (L/kg) 1.668 ± 0.730 1.313 ± 0.838 
MRT (h) 17.154 ± 6.517 26.096 ± 20.598 
AUCinf / D (µg/mL/µg) 0.573 ± 0.053 0.894 ± 0.399 
	  
	  
Plasma concentration-time data of edelfosine in LN were well described by 
bi-exponential functions following i.v. administration of both types of LN. The 
distribution half-lives (t1/2α) of the two formulations were around 0.4 h, while the 
elimination half-lives (t1/2β) were 17 h for Compritol® LN and 23 h for Precirol® 
LN, suggesting a much slower elimination of these last nanoparticles. These 
parameters are higher than those of the edelfosine-loaded liposomes described 
by Bhamra et al. (13.1 h) [6], indicating that these LN circulate in plasma for a 
longer period of time. 
The rest of the pharmacokinetic parameters showed no statistical 
differences between the two types of LN. The mean systemic CL and Vss values 
for edelfosine-loaded LN were around 0.08 L/h/kg and 1.5 L/kg, respectively. 
When edelfosine was loaded into liposomes [6], the Vss was 0.203 L/kg, 7 times 
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lower than this value, suggesting that LN allow a broader distribution of the drug 
in the body. There was little variability in most of the values of the 
pharmacokinetic parameters, indicating a well-controlled and reproducible 
study, except for the elimination phase half-life value. AUC values were 
between 0.6 and 0.9 µg·h/mL/µg, similar to those obtained in a previous 
research work [2] after the i.v. administration of edelfosine solution, indicating 
that the i.v. administration of edelfosine in LN presents an absolute 
bioavailability of 100 %.  
Figure 2 depicts the scattering of the drug through the mouse body after i.v. 
administration of edelfosine-loaded LN, expressed as tissue/plasma ratios.  
 
Figure 2. Tissue/plasma concentration ratios of edelfosine after a single intravenous 
dose of edelfosine-loaded Compritol® and Precirol® LN to BALB/c mice (n=8) 
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Whichever the type of nanoparticle employed, the highest accumulations of 
the drug were achieved in kidney, intestine and liver, followed by spleen, 
stomach and lung, with no statistical differences between the ratios.  
3.5. Pharmacokinetic characterization and biodistribution after oral 
administration 
Pharmacokinetic studies were performed after a single oral administration 
of 50 mg/kg of edelfosine-loaded in LN. This oral dose was well tolerated by the 
mice and no hemolytic side effects or body weight loss was observed (data not 
shown). Figure 3 shows the concentration of edelfosine in mouse plasma 
plotted against time after a single oral administration of edelfosine-loaded LN to 
BALB/c mice.  
 
Figure 3. Time-plasma concentration curve data of edelfosine obtained with the 
WinNonLin program after a single oral administration of edelfosine solution and 
edelfosine loaded Compritol® and Precirol® LN to mice (n=8 per group) 
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The endpoint of the experiment was the day after the concentration of 
edelfosine in plasma reached 0.5 µg/mL. It can be observed that unlike 
edelfosine solution, drug-loaded LN enhanced the absorption of the drug 
maintaining detectable concentrations for over seven days. As a result, the 
maintenance times in plasma achieved with the developed LN were much 
longer than those observed by different studies recently published with the 
same Compritol® lipid, which did not last longer than 24 h [27, 32].  
All dose-normalized pharmacokinetic parameters obtained after the 
administration of edelfosine in LN are summarized in Table III.  
 
Table III. Comparison of pharmacokinetic parameters of edelfosine after oral 
administration of edelfosine loaded LN (50 mg/kg bw, n=8 per group, mean ± SD). 
Asterisks indicate significantly different values between the two types of LN, p<0.05 (*) 
and p<0.01 (**) by Mann-Whitney test. 
Parameters 
Compritol® 888 ATO LN 
oral administration 
Precirol® ATO 5 LN 
oral administration 
t½ (h) 37.652 ± 12.187 45.221 ± 14.564 
t½Ka (h) 4.938 ± 1.818 4.045 ± 1.873 
Cmax / D (µg/mL/µg) 0.007 ± 0.001 0.012 ± 0.006** 
Tmax (h) 15.890 ± 2.839 14.663 ± 4.150 
CL (L/h/kg) 0.045 ± 0.009 0.034 ± 0.009* 
Vss (L/kg) 2.343 ± 0.483 2.425 ± 1.274 
MRT (h) 39.155 ± 7.656 52.919 ± 4.068* 
AUCinf / D (µg/mL/µg) 0.635 ± 0.103 0.813 ± 0.155* 
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The maximum concentration (Cmax/dose) after the administration was 0.007 
± 0.001 µg/mL/µg and 0.012 ± 0.006 µg/mL/µg for Compritol® and Precirol® LN, 
respectively, after 15 h, which is the time at which peak concentration is 
reached (Tmax). In previous studies, we hypothesized that the interaction of 
edelfosine with P-glycoprotein (P-gp) could be the explanation for the lack of 
gastrointestinal absorption of the drug [2]. However, the Tween® 80 present in 
the composition of the LN shows an inhibition effect of P-gp [33, 34]. Therefore, 
both types of edelfosine-loaded LN crossed the gastrointestinal barrier and 
prolonged the release of the drug for over one week. Different authors had also 
observed this effect, after they administered different drugs via the oral route 
[26, 35-38]. The AUC(0-24) values after the oral administration of edelfosine in LN 
were much higher (15-fold) than those after oral administration of edelfosine in 
solution. The oral bioavailability of edelfosine 24 h after the oral administration 
of 30 mg/kg of edelfosine in solution was proved to be less than 10 % [2]. 
Owing to the expected slow release of edelfosine from the LN, it was decided to 
test a higher dose (50 mg/kg, a dose at which edelfosine still presents linear 
pharmacokinetics, data not shown) than that used for previous studies, to 
determine the pharmacokinetic and biodistribution profile of edelfosine-loaded 
in LN. As a result, the encapsulation of edelfosine in LN provided an increase in 
relative oral bioavailability of 1500 %. It is interesting to note that even if 
multiple administration of free edelfosine was able to increase the bioavailability 
of the drug up to 64 %, it presents the drawback of causing gastrointestinal 
irritation [4, 5]. On the other hand, the oral administration of LN greatly 
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increased the bioavailability of the drug with just a single dose avoiding the GI 
toxicity. 
The mean systemic CL for orally administered edelfosine-loaded LN 
presented statistically significant differences. The value was 0.045 L/h/kg for 
Compritol® LN and 0.034 L/h/kg for Precirol® LN. These values represent half 
the value of that of intravenously administered LN, presenting statistical 
differences (p<0.05). This decrease in the CL values is responsible for the 
longer permanence of the particles in plasma. Vss presented a value of 2.4 L/kg, 
doubling the value of that of intravenously administered particles. This appears 
to suggest that there is higher tissue distribution of the drug when LN are 
administered orally, compared to an i.v. administration of same particles.  
Mean residence time (MRT) of orally administered edelfosine-loaded LN 
was 39 and 53 h for Compritol® and Precirol® LN, respectively, which is 
approximately three times the value of edelfosine solution administered orally 
(14 h) and twice that of intravenously administered drug-loaded LN (17 and 26 
h, for Compritol® and Precirol®, respectively). These observations suggest a 
partial indirect absorption of edelfosine-loaded LN after oral administration. It 
has been described in the literature that the possible mechanisms of the 
gastrointestinal uptake of colloidal carriers include 3 pathways: an intracellular 
uptake, a paracellular uptake and an uptake via the M-cells and the Peyer’s 
patches [39]. In fact, different theories have been proposed to study the uptake 
of lipophilic drugs using nanoparticles. The main uptake has been shown to 
happen either via isolated lymphoid follicles or by Peyer’s patches after oral 
administration, as reported by Florence et al. [40]. Still, in the last decade some 
papers have reported that both systemic exposure of a lipophilic drug and 
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lymphatic transport are enhanced after coadministration with lipidic vehicles, 
and variations in the composition of the lipid formulation may lead not only to 
the promotion of significant changes in drug transport via the lymphatic system 
but may also bring about changes in systemic plasma levels [41]. 
The avoidance of the presystemic metabolism in the liver (first-pass effect) 
is one of the most important advantages that lymphatic absorption of a drug 
may provide via the portal route after gastrointestinal administration. Besides, 
lymphatic targeting may also be of interest to enhance oral absorption of 
macromolecules, in order to achieve different goals, as it may bring about an 
improvement in lymphatic anti-cancer therapy. In order to confirm this lymphatic 
absorption, another in vivo experiment was performed in BALB/c mice, in which 
mesenteric lymph nodes were extracted and analyzed 24 h after the oral 
administration of LN and free edelfosine. Free drug treated animals showed 
drug amounts below the limit of quantitation of the chromatographic technique, 
while Compritol LN treated mice presented a mean concentration of 18.6 µg/g 
lymph node, while Precirol LN treated ones had 16.4 µg/g lymph node, 
confirming a high lymphatic absorption of the LN. Our results are in accordance 
with a study in which another cytotoxic drug (methotrexate) was encapsulated 
into Compritol® LN and orally administered [27]. In this study, a periodic 
lymphatic concentration of methotrexate following oral administration of LN-
based formulations was determined by mesenteric duct cannulation and 
collection of samples. This study revealed that the formulation based on 
Compritol® 888 ATO could noticeably improve the oral bioavailability of the 
drug, presumably following LN constituting lipid digestion and co-absorption 
through lymphatic transport and route. 
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The tissue distribution expressed as edelfosine concentration after the 
administration of a drug dose of 50 mg/kg to mice is shown in Figure 4.  
 
Figure 4. Tissue/plasma concentration ratios of edelfosine after a single oral dose of 
edelfosine-loaded Compritol® and Precirol® LN to BALB/c mice (n=8 per group, mean ± 
SD). 
Compritol® LN treated animals were sacrificed 168 h post-administration, 
while mice treated with Precirol® LN were sacrificed 216 h post-administration, 
because it was at these time points when the edelfosine concentration in 
plasma was below 0.5 µg/mL. It was observed that edelfosine was mainly 
scattered through the major drug clearance tissues liver and kidney, along with 
the intestine, the typical organ for phospholipid elimination. This accumulation is 
probably due to the previously mentioned P-gp inhibiting properties of Tween® 
80, as these organs present high expression of P-gp [42] 
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3.6. In vivo efficacy of edelfosine-loaded LN 
Previous studies have provided evidence for the uptake and transport of LN 
in the lymph and, to a lesser extent, in the blood [43]. Therefore, due to the 
ability of the developed LN to be absorbed by the lymphatic system, we 
hypothesized that LN could be able to treat lymphatic diseases, and in 
particular, lymphomas. 
It is known that the therapy for lymphatic neoplasms is comprised of 
different drugs that always involve several hematological side effects [20]. 
Edelfosine lacks those negative secondary effects because it causes no 
mielotoxicity [1]. Besides, this drug has already been effective in in vitro 
experiments against JVM-2 mantle-cell lymphoma cell line [44]. However, we 
have to bear in mind that edelfosine presents low bioavailability [2] and may 
cause hemolysis at high concentrations [31]. In this study, LN with a suitable 
size for oral administration have been developed; these LN increase the 
bioavailability and avoid hemolysis, so an in vivo experiment was designed with 
MCL-bearing mice to evaluate the efficacy of the drug-loaded LN (Figure 5). It is 
remarkable that a daily administration of 30 mg/kg edelfosine was mandatory to 
diminish the tumor burden of MCL bearing mice as much as Compritol® and 
Precirol® LN did after the treatment every four days (Figure 5A). Besides, the 
treatment of mice with Compritol® LN every four days reduced the tumor weight 
more efficiently than the daily administration of edelfosine solution (Figure 5B). 
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Figure 5. Differences in A) volume and B) weight of implanted mantle-cell lymphoma 
xenograft tumors 20 days after a treatment of daily PBS (control), daily edelfosine 
solution (30 mg/kg bw) and Compritol® and Precirol® LN every four days (30 mg/kg bw) 
(n=8 per group, mean ± SD). *p<0.05; **p<0.01 by Student’s t test 
From these results it can be concluded that the oral administration of 
edelfosine-loaded LN every four days was as effective against a xenograft 
model of lymphoma as the daily oral administration of the free drug. Regarding 
tumor weight, both types of nanoparticles reduced the weight of the tumor 
significantly, compared to the control. These data show that edelfosine-loaded 
LN present a potential anti-lymphoma effect and could be tested as treatment 
against lymphomas. Besides, these drug-loaded nanoparticulate systems do 
not present the side effects that other antineoplastic drugs do [16, 45]. 
Due to the confirmation that edelfosine-loaded LN circulate through lymph 
nodes, by the present study as well as by other researchers [32], we also 
wanted to assess the ability of these delivery systems to inhibit extranodal 
dissemination of MCL cells. For that reason, axilary, inguinal and mesenteric 
lymph nodes were also extracted from MCL-bearing mice treated with either 
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free or vectorized edelfosine and macroscopically analyzed. As can be seen in 
Figure 6, all the lymphatic metastases were not completely removed after the 
treatment with a daily oral administration of edelfosine solution to mice, and a 
certain degree of extranodal dissemination could still be observed.  
 
Figure 6. Representation of the antimetastatic efficacy of LN, expressed as the 
measurement of the volume of metastatic nodes, 20 days after a treatment of daily 
PBS (control), daily edelfosine solution (30 mg/kg bw) and Compritol® and Precirol® LN 
every four days (30 mg/kg bw) (n=8 per group, mean ± SD). **p<0.01 by Student’s t 
test	  
However, the administration of edelfosine-loaded LN every four days 
completely eradicated the metastasization process, leaving no sign of 
extranodal dissemination. Lu et al. obtained similar results using Compritol® LN 
against breast cancer and its metastases after a local injection; however, they 
did not achieve complete eradication of the extranodal dissemination [46]. This 
complete inhibition of the metastases can be mainly attributed to the lymphatic 
absorption and accumulation of LN in the thoracic duct, which acts as a 
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reservoir, and from which LN are continuously released throughout lymph 
nodes. This outcome is of great interest in the treatment of different types of 
lymphomas, especially via the oral route, as no orally administered treatments 
have been described yet [47, 48]; therefore, our results concerning edelfosine-
loaded LN as being effective against both MCL and its lymph node metastases 
shows a strong potential to benefit the improvement of clinical efficiency. 
 
4. Conclusions 
The data presented above give evidence that it was possible to produce LN 
endowed with high encapsulation efficiency and with a well-determined size 
distribution. Moreover, the incorporation of edelfosine in LN greatly improves 
the oral bioavailability of the drug. These LN that are uptaken by the lymphatic 
system offer a selective accumulation in lymph, showing effectiveness against 
mantle-cell lymphoma, and an important antimetastatic effect. All the results in 
this work show great promise for the oral treatment of lymphomas and the 
eradication of extranodal dissemination, as no such treatment is yet available in 
clinical practice. 
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Future perspective 
The development of LN that target the extranodal dissemination of 
hematological disorders opens a promising path in the treatment of these 
diseases. New therapies using drug loaded LN will be designed to focus and 
increase the therapeutic efficacy of drugs against diseases, while decreasing 
their secondary effects. Moreover, the oral administration of these delivery 
systems will increase the patients’ compliance. 
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Executive Summary 
- Edelfosine loaded lipid nanoparticles increased oral bioavailability in 
1500%.  
- Lipid nanoparticles were absorbed through the lymphatic system.  
- Drug loaded lipid nanoparticles inhibited 100% of extranodal 
dissemination in mantle cell lymphoma bearing mice. 
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